AEON Biopharma Holds Meeting With FDA for Botox Biosimilar

Dow Jones

01/22

By Kelly Cloonan

AEON Biopharma met with the Food and Drug Administration regarding its biosimilar for Botox and plans to comment on the meeting after receiving official minutes.

The biopharmaceutical company said Wednesday it held a scheduled BPD Type 2a meeting, which is meant to focus specifically on a narrow set of issues. The meeting aimed to review AEON's analytical development plan and initial data supporting biosimilarity, AEON said in November.

The company expects the minutes to inform its next steps for the development of ABP-450, Chief Executive Rob Bancroft said. It is seeking accelerated and full-label U.S. market entry for ABP-450.

"The completion of our BPD Type 2a meeting with FDA represents an important procedural milestone," Bancroft said.

Write to Kelly Cloonan at kelly.cloonan@wsj.com

(END) Dow Jones Newswires

January 21, 2026 16:46 ET (21:46 GMT)

應版權方要求，你需要登入查看該內容

登入 / 註冊

免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。

熱議股票

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎證券,老虎證券開戶,老虎券商,老虎證券官網,老虎證券app,tigertrade老虎證券,股票,炒股,新加坡股票交易平臺,投資,投資理財","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hant/news/2605435901"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2605435901\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2605435901?lang=zh_TW&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-01-22 05:46","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2605435901","market":"nz","top_or_hot":-1,"title":"AEON Biopharma Holds Meeting With FDA for Botox Biosimilar","media":"Dow Jones","content":"<font class=\"NormalMinus1\" face=\"Arial\">\n<p>\n  By Kelly Cloonan \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  <a href=\"https://laohu8.com/S/AEON\">AEON Biopharma</a> met with the Food and Drug Administration regarding its biosimilar for Botox and plans to comment on the meeting after receiving official minutes. \n</p>\n<p>\n  The biopharmaceutical company said Wednesday it held a scheduled BPD Type 2a meeting, which is meant to focus specifically on a narrow set of issues. The meeting aimed to review AEON's analytical development plan and initial data supporting biosimilarity, AEON said in November. \n</p>\n<p>\n  The company expects the minutes to inform its next steps for the development of ABP-450, Chief Executive Rob Bancroft said. It is seeking accelerated and full-label U.S. market entry for ABP-450. \n</p>\n<p>\n  \"The completion of our BPD Type 2a meeting with FDA represents an important procedural milestone,\" Bancroft said. \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  Write to Kelly Cloonan at kelly.cloonan@wsj.com \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  January 21, 2026 16:46 ET (21:46 GMT)\n</p>\n<p>\n  Copyright (c) 2026 Dow Jones &amp; Company, Inc.\n</p>\n</font>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>AEON Biopharma Holds Meeting With FDA for Botox Biosimilar</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nAEON Biopharma Holds Meeting With FDA for Botox Biosimilar\n</h2>\n<h4 class=\"meta\">\n<div class=\"head\" \">\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Dow Jones </p>\n<p class=\"h-time smaller\">2026-01-22 05:46</p>\n</div>\n</div>\n</h4>\n</header>\n<article>\n<font class=\"NormalMinus1\" face=\"Arial\">\n<p>\n  By Kelly Cloonan \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  <a href=\"https://laohu8.com/S/AEON\">AEON Biopharma</a> met with the Food and Drug Administration regarding its biosimilar for Botox and plans to comment on the meeting after receiving official minutes. \n</p>\n<p>\n  The biopharmaceutical company said Wednesday it held a scheduled BPD Type 2a meeting, which is meant to focus specifically on a narrow set of issues. The meeting aimed to review AEON's analytical development plan and initial data supporting biosimilarity, AEON said in November. \n</p>\n<p>\n  The company expects the minutes to inform its next steps for the development of ABP-450, Chief Executive Rob Bancroft said. It is seeking accelerated and full-label U.S. market entry for ABP-450. \n</p>\n<p>\n  \"The completion of our BPD Type 2a meeting with FDA represents an important procedural milestone,\" Bancroft said. \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  Write to Kelly Cloonan at kelly.cloonan@wsj.com \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  January 21, 2026 16:46 ET (21:46 GMT)\n</p>\n<p>\n  Copyright (c) 2026 Dow Jones &amp; Company, Inc.\n</p>\n</font>\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"AEON","symbol_name":"AEON Biopharma","start_time":0,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","article_id":"2605435901","we_media_id":"106","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2605435901","pubTimestamp":1769031960,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Dow Jones","introduction":"Dow Jones publishes the world’s most trusted business news and financial information in a variety of media.","home_visible":0,"id":"106","head_image":"https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99"},"summary":"AEON Biopharma met with the Food and Drug Administration regarding its biosimilar for Botox and plans to comment on the meeting after receiving official minutes.The biopharmaceutical company said Wednesday it held a scheduled BPD Type 2a meeting, which is meant to focus specifically on a narrow set of issues. The meeting aimed to review AEON's analytical development plan and initial data supporting biosimilarity, AEON said in November.The company expects the minutes to inform its next steps for the development of ABP-450, Chief Executive Rob Bancroft said. It is seeking accelerated and full-label U.S. market entry for ABP-450.\"The completion of our BPD Type 2a meeting with FDA represents an important procedural milestone,\" Bancroft said.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"AEON":"AEON Biopharma","BK4139":"生物科技"},"translate_title":"永旺生物制药与FDA就肉毒杆菌生物仿制药举行会议","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"AEON":1.5},"content_text":"By Kelly Cloonan \n\n\n \n\n\nAEON Biopharma met with the Food and Drug Administration regarding its biosimilar for Botox and plans to comment on the meeting after receiving official minutes. \n\n\n  The biopharmaceutical company said Wednesday it held a scheduled BPD Type 2a meeting, which is meant to focus specifically on a narrow set of issues. The meeting aimed to review AEON's analytical development plan and initial data supporting biosimilarity, AEON said in November. \n\n\n  The company expects the minutes to inform its next steps for the development of ABP-450, Chief Executive Rob Bancroft said. It is seeking accelerated and full-label U.S. market entry for ABP-450. \n\n\n  \"The completion of our BPD Type 2a meeting with FDA represents an important procedural milestone,\" Bancroft said. \n\n\n \n\n\n  Write to Kelly Cloonan at kelly.cloonan@wsj.com \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  January 21, 2026 16:46 ET (21:46 GMT)\n\n\n  Copyright (c) 2026 Dow Jones & Company, Inc.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":true,"code":"91000000","status":"200"}}}